TIRmed Pharma initiates collaboration with ERBC for regulatory safety studies ahead of its first clinical trial
TIRmed Pharma, a biotechnology company developing next-generation treatments for autoimmune skin diseases, has entered into a collaboration with ERBC, a leading European CRO specialized in toxicology studies. The partnership covers two regulatory safety studies, marking the final steps ahead of the company’s planned Phase I clinical trial in 2026.[TIRmed-Pharma-initiates-collaboration-ERBC.jpg]
These studies represent the final preclinical steps for TIR-C, TIRmed’s topical drug candidate for the treatment of atopic dermatitis (eczema). The first safety study has already begun, and the
